Business Context and Reporting Period
This Form 8-K Current Report was filed by CytoSorbents Corporation on February 3, 2016. The filing primarily addresses a corporate governance matter under Item 5.02 regarding the appointment of certain officers and compensatory arrangements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a specific executive agreement rather than periodic financial performance.
Material Changes
On February 3, 2016, the Company entered into a consulting agreement (the "Bartlett Agreement") with Dr. Robert H. Bartlett, its Chief Medical Officer. Key terms include:
- Term: Initial term of two years, retroactively effective as of January 1, 2015.
- Compensation: Monthly consulting fee of $4,500 plus reimbursement for reasonable business expenses.
- Provisions: Includes customary non-competition and non-disclosure clauses.
Guidance, Outlook, and Risks
The filing contains no management commentary regarding future guidance, outlook, or specific risks beyond the standard contractual obligations of the consulting agreement. No unusual items or contingencies were disclosed in this report.
Investor Verification Checklist
- Verify the full text of the Consulting Agreement attached as Exhibit 10.1 for complete terms.
- Confirm the retroactive effective date of January 1, 2015, and its impact on prior period expense recognition.
- Review subsequent filings to determine if Dr. Bartlett's role or compensation has been modified.